Aurobindo Pharma Ltd
₹1705
+10.50 (0.62%)
Fri, 06 Nov 2026, 10:01 pm
Aurobindo Pharma News
Aurobindo Pharma targets FY28 growth via Lannett and China
Aurobindo Pharma expects FY28 to surpass FY27 due to full Lannett contributions, increased China production, and biosimilar growth. China facility aims for break-even by Q3FY27.
05 Nov 2026
companies
Aurobindo Pharma reappoints Kumar as Independent Director
Aurobindo Pharma board approves re-appointment of Mangalam Ramasubramanian Kumar as Independent Director for a second five-year term starting April 2027.
04 Nov 2026
companies
Aurobindo Pharma transfers Russia stake
Aurobindo Pharma approved internal transfer of Auro Pharma LLC from Auro Active Pharma to Auropharm Overseas. The transaction, valued at ₹29 crore, streamlines group holdings.
04 Nov 2026
companies
Aurobindo Pharma merges two API subsidiaries
Aurobindo Pharma board approved merger of wholly owned subsidiaries Auroactive and Apitoria to consolidate API operations and improve efficiency.
04 Nov 2026
companies
Aurobindo Pharma Q2FY27 PAT jumps 24% to ₹11,238 crore
Aurobindo Pharma reported a 24% YoY rise in consolidated net profit for Q2FY27, driven by strong revenue growth and the Lannett acquisition.
04 Nov 2026
companies
Market Current News
CONTINENTAL CONTROLS LTD.
Continental Controls rights issue oversubscribed
Continental Controls Limited completed its rights issue of 1.96 crore shares at ₹10 each. The issue was oversubscribed 112.75% and shares list on BSE on November 5, 2026.
05 Nov 2026
ipo
Jivial Industries Limited
Jivial Industries changes IPO machinery vendors
Jivial Industries Ltd approved partial vendor changes for three machinery sets in its IPO project. Costs and timelines remain unchanged despite the switch.
05 Nov 2026
ipo
Antala IPO Day 6: Subscribed 6.43x
Antala Industries IPO sees strong QIB demand at 66.72x on final day. Total subscription reaches 6.43x as Retail and NII interest picks up.
05 Nov 2026
ipo
IGL Spirits lists on BSE and NSE post-demerger
IGL Spirits Limited listed on BSE and NSE on November 4, 2026. The demerged entity reported FY26 revenue of ₹2,801 crore and EBITDA of ₹492 crore.
04 Nov 2026
ipo
Ennature Bio Pharma lists on NSE, BSE
Ennature Bio Pharma Limited listed on NSE and BSE on November 4, 2026. The biopharma division reported ₹246 crore revenue in FY26, driven by branded nutraceuticals.
04 Nov 2026
ipo